German Funds' Multi- Billion Savings Plan
The German health insurance funds have been called on to save 7.5 billion Deutschemarks ($5 billion) as a contribution to the government's savings and consolidation package of public expenditure reductions.
The aim of the program is to stabilize health insurance and social security contributions. Services are to be cut or reduced and income improved in order to provide this stability.
The government has agreed a number of changes to health insurance legislation. The funds are to cut their payments to hospitals by 2.4 billion marks ($1.58 billion) over the next three years. Drug prescription charges will go up, with patients paying 4 marks for medium-sized packs and 8 marks for large packs, a move that is expected to generate extra income of 700 million marks ($461.4 million). A number of other measures affecting "cures" have also been announced.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze